Apoptosis: Molecular mechanisms and implications for cancer chemotherapy

Pharmacy World and Science

Volumn 19, Issue 3, 1997, Pages 119-125

  Guchelaar, H J ^a   Vermes, A ^a   Vermes, I ^b   Haanen, C ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Apoptosis; Chemotherapy; Drug resistence; Necrosis; P53 tumor suppressor gene; Programmed cell death

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN;

APOPTOSIS; CANCER CHEMOTHERAPY; GENE EXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; ONCOGENE; PHARMACODYNAMICS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COMBINED MODALITY THERAPY; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; NEOPLASMS;

EID: 0030752050     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008654316572     Document Type: Review

References (93)

1. Kerr JFR. Shrinkage necrosis: a distinct mode of cellular death. JPathol 1971;105:13-20.
2. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br JCancer 1972;26:239-57.
3. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
4. Ellis RE, Yuan JY, Horvitz HR. Mechanismsand functions of cell death. Annu Rev Cell Biol 1991;7:663-98.
5. Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990;68:1071-4.
6. Bursch W, Paffe S, Putz B, Barthel G, Schulte-Hermann R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci in rats. Carcinogenesis 1990;11:847-53.
7. Cohen JJ. Apoptosis. Immunol Today 1993;14:126-30.
8. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
9. Reed JC. Minireview: cellular mechanisms of disease series. Bcl-2 and the regulation of programmed cell death. JCell Biol 1994;124:1-6.
10. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
11. Yonehara S, Ishii A, Yonehara M. A cell killing monoclonal antibody (anti-FAS) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
12. 2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today 1995;16:524-8.
13. Ferguson DJP, Anderson TJ, Ultrastructural observations on cell death by apoptosis in the 'resting' human breast. Virchows Arch 1981;393:193-203.
14. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flowcytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 1995;184:39-51.
15. Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995;20:73-7.
16. Obeid LM, Hannun YA. Ceramide: A stress signal and mediator of growth suppression and apoptosis. J Cell Biochem 1995;58:191-8.
17. Pushkareva M, Obeid LM, Hannun YA. Ceramide: an endogenous regulator of apoptosis and growth suppression, Immunol Today 1995;16:294-7.
18. Green DR, Martin SJ. The killer and the executioner: how apoptosis controls malignancy. Curr Opin Immunol 1995;7:694-703.
19. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS, Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-3.
20. Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 1994;371:519-23.
21. Richter C, Schweizer M, Cossarizza A, Franceschi C. Control of apoptosis by the cellular ATP level. FEBS Lett 1996;378:107-10.
22. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
23. Craig RW. The BCL-2 gene family. Cancer Biol 1995;6:35-43.
24. White E. Life, death, and the pursuit of apoptosis. Genes Developm 1996;10:1-15.
25. Tsujimoto Y, Gorham J, Coosman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-3.
26. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer S. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
27. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax that accelerates programmed cell death. Cell 1993;74:609-19.
28. Nunez G, Merino R, Grillot D, Gonzalez-Garcia M. Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today 1994;15:582-8.
29. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 1995;13:513-43.
30. Kumar S. ICE-like proteases in apoptosis. Trends Biochem Sc 1995;20:198-202.
31. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer and Metast Rev 1995;14:149-61.
32. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl JMed 1993;329:1318-26.
33. Levine AJ, Momand J, Finlay CA The p53 tumour suppressor gene. Nature 1991;351:453-6.
34. Carson DA. Cancer progression and p53. Lancet 1995;346:1009-11.
35. Lane DP. F53, guardian of the genome. Nature 1992;358:15-16.
36. Fésüs L, Szondy Z, Uray I. Probing the molecular program of apoptosis by cancer chemopreventive agents. JCell Biochem 1995;22(suppl):151-61.
37. Martin SJ, Green DR. Protease activation during apoptosis; death by thousand cuts? Cell 1995;82:345-52.
38. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium dependent endonuclease in thymocyte nuclei leads to cell death. JImmunol 1984; 132:138-42.
39. Cohen JJ, Duke RC, Chervenak R, Sellins KS, Olson LK. DNA fragmentation in targets of CTL: an example of programmed cell death in the immune system. Adv Exp Med Biol 1985;184:493-508.
40. Murgia M, Pizzo P, Sandona D, Zanovello P, Rizzuto R. Di Virgilio F. Mitochondrial DNA is not fragmented during apoptosis. JBiol Chem 1992;267:1039-41.
41. McConkey DJ, Hartzell P, Nicotera P, Orrenius S. Calcium activated DNA fragmentation kills immature thymocytes. FASEB J 1989;3:1843-9.
42. Zheng LM, Zychilinsky A, Liu CC, Ojcius DM, Young JDE Extracellular ATP as a trigger for apoptosis or programmed cell death. JCell Biol 1991;112:279-88.
43. Jacobson MD, Burne JF, Raff MC. Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J 1994;13:1899-910.
44. Schulze-Osthoff K, Walczak H, Droge W, Krammer PH. Cell nucleus and DNA fragmentation are not required for apoptosis. JCell Biol 1994;127:15-20.
45. Lazebnik YA, Cole S, Cooke CA, Nelson WG, Earnshaw WC. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. JCell Biol 1993;123:7-22.
46. Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994;79:353-64.
47. Morris RG, Hargreaves AD, Duval E, Wyllie AH. Hormone-induced death. II. Surface changes in thymocytes undergoing apoptosis. Am JPathol 1984;115:426-31.
48. Savill JS, Henson PM, Haslett C. Phagocytosis of aged human neutrophils by macrophages is mediated by a novel 'charge-sensitive' recognition mechanism. J Clin Invest 1989;84: 1518-27.
49. Savill J, Fadok V, Henson P, Haslett C. Phagocyte recognition of cell undergoing apoptosis. Immunology Today 1993;14:131-6.
50. Savill JS, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990;343:170-3.
51. Savill JS, Wyllie AH, Henson JE, Walport MJ Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989;83:865-75.
52. Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Cambell PA, Henson PM. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol 1992;149:4029-35.
53. Fadok VA, Laszlo DJ, Noble PW, Weinstein L, Riches DWH, Henson PM. Particle digestibility is required for induction of the phosphatidylserine recognition mechanism used by murine macrophages to phagocytose apoptotic cells. J Immunol 1993;151:4274-85.
54. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognation and removal by macrophages. JImmunol 1992;148:2207-16.
55. Martin SJ, Reutelingsperger CPM, McGahon AJ, Rader JA, van Schie RCAA, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition of Bcl-2 and AbI. JExp Med 1995;182:1545-56.
56. Hall SE, Savill JB, Henson PM, Haslett C. Apoptotic neutrophils are phagocytosed by fibroblast with participation of the fibroblast vitronectin receptor and involvement of a mannose/fucose-specific lectin. JImmunol 1994;153:3218-27.
57. Flora PK, Gregory CD. Recognition of apoptotic cells by human macrophages: inhibition by a monocyte/macrophage-specific monoclonal antibody. Eur J Immunol 1994;24:2625-32.
58. Bright JJ, Khar A. Apoptosis: programmed cell death in health and disease. Bioscience Rep 1994;14:67-81.
59. Lowe SW, Ruley HE, Jacks T, Housman DE P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
60. Henriksen R, Wilander E, Öberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-9.
61. Törmänen U, Eerola AK, Rainio P, Vähäkangas K, Soini Y, Sormunen R, Bloign R, Lehto VP, Pääkkö R. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995;55:5595-602.
62. Borg A, Lennerstrand J, Stenmark-Askmalm M, Fernö M, Brisfors A, Öhrvik A, Stal O, Killander D, Lane D, Brundell J. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br JCancer 1995;71:1013-17.
63. Binder C, Marx D, Binder L, Schauer A, Hiddeman W. Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann Oncol 1996;7:129-33.
64. Hellemans P, Dam van PA, Weyler J, Oosterom van AT, Buytaert P, Marck van E. Prognostic value of bcl-2 expression in invasive breast cancer. Br JCancer 1995;72:354-60.
65. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-39.
66. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192-6.
67. Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-Cancer Drugs 1994;5:3-9.
68. Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am JPath 1994;144:1045-66.
69. Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anti-Cancer Drugs 1995;6:443-50.
70. Guchelaar H-J, Vermes I, Kalsbeek-Batenburg E, Haanen C. A novel flowcytometric assay allows in vitro assessment of the apoptosis- and necrosis inductive potential of anticancer drugs and combined treatment. Proc Am Soc Clin Oncol 1996;89 (abstract 23).
71. Gruber J, Grell R. Apoptosis and therapy of malignant diseases of the hemotopoietic system. Int Arch Allergy Immunol 1994;105:368-73.
72. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995;36:181-8.
73. Sen S, D'lncalci M. Biochemical events and relevance to cancer chemotherapy. FEBS 1992;307:122-7.
74. Zinzani PL, Tosi P, Visani G, Martinelli G, Farabegoli P, Buzzi M, Ottaviani E, Salvucci M, Bendandi M, Zaccaria A, Tura S. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia celss. Am JHematol 1994;47:301-6.
75. Hutschtscha LI, Bartier WA, Malmstrom A, Tattersall MHN. Cell death by apoptosis following anticancer drug treatment in vitro, Int JOncol 1995;6:585-93.
76. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-62.
77. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996;32a:921-6.
78. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989;49:5870-8.
79. Meyn RE, Stephens LC, Hunter NR, Milas L. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994;33:410-4.
80. Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR, Darzynkiewicz Z. Induction of DNA strand breaks associated with apoptosis during treatment of leukemia. Leukemia 1993;7:659-70.
81. Idink CAM, Schaafsma MR, Vermes I, Guchelaar HJ, Kalsbeek E, Richel DJ. 2-Chlorodeoxyadenosine (2-CDA) induced apoptosis in patients with hairy cell leukemia. Proc Am Soc Clin Oncol 1996;89 (abstract 24).
82. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54;2287-91.
83. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993;341:1251-4.
84. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. P53 status and the efficacy of cancer therapy in vivo. Science 1994;266:805-10.
85. Evans DL, Tilby M, Dive C. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of levels of drug accumulation and DNA adduct formation. Cancer Res 1994;54:1596-603.
86. D'Amico AV, McKenna WG. Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiother and Oncol 1994;33:3-10.
87. Malcomson RDG, Oren M, Wyllie AH, Harrison DJ. F53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 1995;72:952-7.
88. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U, Mueller H. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994;344:1647-8.
89. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53:4164-8.
90. Aldridge DR, Arends MJ, Radford IR. Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival doeseresponse. Br JCancer 1995;71:571-7.
91. Dheln J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
92. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
93. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol/Hematol 1995;18:137-53.